托珠单抗单药治疗大血管炎的104周前瞻性开放研究
结果显示GCA患者在24周和52周的完全/部分缓解率分别为75%和66%,TAK患者分别为25%和0%;5例GCA和1例TAK患者在停药后1年保持无病状态。
要点
- 托珠单抗单药治疗新诊断LVV显示高缓解率,GCA应答优于TAK。
- 多数患者在停用托珠单抗后1年内未复发。
- 1例GCA患者因心力衰竭在24周停用托珠单抗。
核心结论
- 托珠单抗单药治疗新诊断大血管炎患者显示高应答率,且多数患者停药后1年内未复发。
主要发现
- GCA患者在24周和52周的完全/部分缓解率分别为75%和66%,TAK患者分别为25%和0%。
- 5例GCA患者和1例TAK患者在末次TCZ给药后1年保持无病状态。
- 1例GCA患者在24周因心力衰竭需停用TCZ。
关键数值与推荐
- 完全缓解和部分缓解定义为所有临床症状消失或改善且CRP正常化。
- 复发定义为临床症状加重或复发、归因于血管炎的CRP升高和/或需要启动糖皮质激素和/或免疫抑制剂。
- TCZ剂量为8 mg/kg,前2个月每2周一次,后10个月每4周一次,单药治疗不用糖皮质激素或免疫抑制剂。
临床怎么用
- 结果提示托珠单抗单药可作为新诊断LVV(尤其GCA)的治疗选择,但TAK应答率较低需谨慎评估。
- 停用托珠单抗后1年内多数患者未复发,支持IL-6在LVV发病中起关键作用。
局限性
- 样本量小(最终分析11例),单中心、开放标签设计,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for large vessel vasculitides (LVV), including Takayasu arteritis (TAK) and GCA. METHODS: Twelve patients with a newly diagnosed LVV (eight GCA, four TAK) were enrolled. One TAK patient withdrew consent, so 11 (eight GCA, three TAK) were analysed in a prospective, open-label study. TCZ (8 mg/kg) monotherapy, without glucocorticoids or immunosuppressants, was administered every 2 weeks for 2 months and then every 4 weeks for 10 months. Patients were followed for 1 year after the final TCZ dose. Complete and partial responses were defined as disappearance or improvement of all clinical symptoms and normalization of CRP. Relapse was defined as the worsening or recurrence of clinical symptoms, increase in CRP attributable to vasculitis, and/or the need for initiation of glucocorticoids and/or immunosuppressants. Poor clinical response described patients who did not fit the definition of complete response or partial response. RESULTS: Complete and partial responses rates were 75/66% and 25/0% in GCA/TAK patients, respectively, at week 24 and week 52. Five GCA patients and one TAK patient remained disease-free for 1 year after therapy. One GCA patient required TCZ discontinuation due to heart failure at week 24. CONCLUSION: TCZ monotherapy showed a high response rate for newly diagnosed LVV patients, and the majority of patients did not relapse for 1 year after TCZ cessation. Result of this study could help us to understand the crucial role of IL-6 in the pathogenesis of LVV.
引用
- Saito S, Okuyama A, Okada Y, et al. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. Rheumatology (Oxford). 2020. PMID: 31665468. doi:10.1093/rheumatology/kez511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。